Sectoral Asset Management appeared to be the Corporate Investor, which was created in 2000. The leading representative office of defined Corporate Investor is situated in the Montru00e9al. The venture was found in North America in Canada.
The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Sectoral Asset Management, startups are often financed by HealthCap, Astellas Venture Management, Ysios Capital. The meaningful sponsors for the fund in investment in the same round are Ysios Capital, Andera Partners, Versant Ventures. In the next rounds fund is usually obtained by T. Rowe Price, Ysios Capital, Venrock.
Among the most popular portfolio startups of the fund, we may highlight F2G, BioVex, HighLife. The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Personal Health, Medical Device.
This organization was formed by Franklin Berger, Jerome Pfund, Michael Sjostrom. The overall number of key employees were 4.
The usual things for fund are deals in the range of 10 - 50 millions dollars. Opposing the other organizations, this Sectoral Asset Management works on 12 percentage points more the average amount of lead investments. The fund is constantly included in 2-6 investment rounds annually. The top activity for fund was in 2015. The real fund results show that this Corporate Investor is 6 percentage points less often commits exit comparing to other companies. The higher amount of exits for fund were in 2019.
Funds with similar focus
|Amador Holdings||Ciudad De Panamá, Panamá, Panama|
|Cameleon Invest||France, Ile-de-France, Paris|
|Carnegie Technologies||San Antonio, Texas, United States|
|China Health Industry Investment Fund||-|
|Crescent Point Energy||Alberta, Calgary, Canada|
|Cure Kids Ventures||-|
|Fupeng Asset||China, Guangdong, Shenzhen|
|Health for Life Capital fund||-|
|Hebei Jijin||China, Hebei, Hebei|
|Huihua Investment||China, Fenghua, Zhejiang|
|InReach Ventures||England, London, United Kingdom|
|Jinan Tongtai||China, Jinan, Shandong|
|Merrill Lynch Canada Inc||Canada, Ontario, Toronto|
|MiMo Capital||Florida, Miami, United States|
|Pacific 6 Enterprises||California, Long Beach, United States|
|The Sapir Organization||New York, New York, United States|
|Westscheme Pty Limited||Australia, Perth, Western Australia|
|Xingfen Yaotu||China, Zhejiang, Zhoushan|
|$43M||03 Nov 2021||Boston, Massachusetts, United States|
|$70M||29 Oct 2021||San Francisco, California, United States|
|$230M||22 Oct 2021||London, England, United Kingdom|
|$72M||23 Sep 2021||Natick, Massachusetts, United States|
|$80M||16 Sep 2021||Écully, Rhone-Alpes, France|
|$60M||26 Aug 2021||San Diego, California, United States|
|$80M||14 Jul 2021||San Francisco, California, United States|
|$65M||24 Feb 2021||California, United States|
|$80M||11 Feb 2021||San Diego, California, United States|
– Garuda Therapeutics from Cambridge develops off-the-shelf, durable blood stem cell therapies.
– Series A funding of $72m brings company valuation to more than $1b.
– The round was led by Aisling Capital, Northpond Ventures and Orbimed, supported by Cormorant Asset Management, Ridgeback Capital Investments, Monashee Investment Management, Sectoral Asset Management, National Resilience, Inc. (Resilience), Mass General Brigham Ventures, among others.
– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.